Detroit research team to expand imaging technology to guide cancer treatment

June 13, 2017, Wayne State University

A team of Wayne State University and Barbara Ann Karmanos Cancer Institute researchers recently received funding from the National Cancer Institute of the National Institutes of Health to expand the use of Positron Emission Tomography (PET) in cancer therapy.

PET imaging is a common tool used in cancer diagnosis. Wei-Zen Wei, Ph.D., the Herrick Chair of Cancer Research at the Barbara Ann Karmanos Cancer Institute and professor of oncology and immunology and microbiology in the School of Medicine at Wayne State University, along with Nerissa Viola-Villegas, Ph.D., assistant professor of oncology in Wayne State University's School of Medicine and the Karmanos Cancer Institute, plan to expand the use of this technology with the help of the two-year, $368,445 grant, "Directing Cancer Immunotherapy and Real-Time ImmunoPET."

According to Wei, current immune-based therapies are effective in some patients with existing anti-tumor immunity, but most are not responsive, therefore revealing the need for immune priming and non-invasive monitoring strategies.

Wei and Viola-Villegas will expand PET imaging technology for cancer immunotherapy by imaging —the specialized that can trigger tumor-fighting immunity. Cancer treatment that brings more dendritic cells into a tumor is more likely to cure cancer.

"Assessing if cancer treatments are effective is often invasive and difficult," said Joseph Dunbar, Ph.D., director of special operations in the Office of the Vice President for Research at Wayne State. "Drs. Wei and Viola-Villegas' method of using PET imaging will be a less invasive, strong indicator of whether cancer treatments are effective."

The research team will develop new imaging probes to detect dendritic cells in the tumor, which will measure the dendritic cells and predict treatment outcome. Their findings may help develop immunoPET, which, in turn, will guide patient treatment in a non-invasive way.

Explore further: PET radiotracer design for monitoring targeted immunotherapy

Related Stories

PET radiotracer design for monitoring targeted immunotherapy

April 7, 2017
In an article published in the April issue of The Journal of Nuclear Medicine, researchers at Stanford University in California provide a template for assessing new positron emission tomography (PET) radiotracers that can ...

Identifying a novel target for cancer immunotherapy

April 12, 2017
Targeting a molecule called B7-H4—which blocks T-cells from destroying tumor cells—could lead to the development of new therapies that boost the immune system's ability to fight cancer, according to a review published ...

Patients' immune system may influence effectiveness of cancer immunotherapy

April 2, 2017
Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh ...

Vaccine shows promising results for early-stage breast cancer patients

January 3, 2017
Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system to recognize cancer cells and target them for destruction. Researchers ...

Researchers find new driver of an aggressive form of brain cancer

November 15, 2016
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age. The discovery can help researchers ...

Research explains limits of cancer immunotherapy drugs

October 26, 2015
Immunotherapy treatments have proven wildly successful in treating some patients with cancer. But despite this success, the majority of patients do not respond to the treatments.

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.